Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved down to $16.12.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the Israeli Ministry of Health has accepted the regulatory submission of ORLADEYO for the prevention of recurrent attacks in patients with
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that oral, once-daily ORLADEYO™ (berotralstat) is now available for patients with a prescription in Germany.
ORLADEYO was approved